Advancing the Cardiovascular Care of the Oncology Patient — Virtual
Advancing the Cardiovascular Care of the Oncology Patient provides clinicians and researchers with the tools needed to improve patient care in your everyday practice. Save the date for this educational experience designed for you to stay on the leading edge of this rapidly evolving field! Join us in Washington, DC, or virtually as we share emerging strategies and revisit best practices in managing cardiovascular health of cancer patients.
Statement of Need
Cancer remains the second leading cause of death in the United States, exceeded only by heart disease, with an estimated 1.8 million new cases in 2020. Cancer treatment can have a diverse array of long-term and late effects, including cardiovascular events such as heart failure, valvular disease, coronary artery disease, arrhythmia, peripheral arterial disease, and thromboembolic events. In this contemporary treatment era, cardiologists, oncologists, and the entire interprofessional team need to understand the different types of cancers and cancer therapies (e.g., cytotoxic chemotherapy, radiation therapy, transplantation, targeted and immune therapies) and their associated cardiovascular risks, to help mitigate the associated cardiovascular complications.
This educational activity is intended to address the educational needs for cardiologists, oncologists, internists, pharmacists, nurses, and all members of the interprofessional care team who advance the clinical care of, and conduct clinical research that is relevant to, the growing population of cancer patients and survivors at risk for, or suffer from, cardiovascular disease.
The goal of this course is to equip the global cardio-oncology community with actionable science to advance patient-centered, evidence-based cardiovascular and cancer care.
- Discuss the different types, oncologic indications, and mechanisms of action of conventional and modern cancer therapies, their associated cardiotoxicities, and the risks of developing cardiovascular risk factors and cardiovascular disease.
- Implement clinical, imaging and biomarker-guideline recommendations regarding risk stratification and monitoring strategies to detect cardiovascular risk in the oncology patient who have been treated with high cardiovascular risk systemic therapies.
- Apply evidence-based strategies for short- and long-term management of cardiotoxicities in patients with active cancer and survivors who have been treated with high cardiovascular risk systemic therapies.
- Summarize the evidence behind the role of pharmacologic and non-pharmacologic interventions in the prevention and management of cardiotoxicity.
- Identify the overlap between cancer and cardiovascular disease, independent of the cardiotoxicity of cancer therapies, such as clonal hematopoiesis, epidemiologic risk factors, and basic mechanisms.
- Describe the pathophysiologic basis of amyloidosis, as well as diagnostic and treatment strategies.
- Design an interprofessional cardio-oncology care team and a framework to improve the overall cardiovascular care of cancer patients and survivors.
- Describe the impact of health disparities, genomic ancestry, and social determinants of health in cardiovascular disease and cancer outcomes.
Ana Barac, MD, PhD, FACC
Medstar Heart and Vascular Institute
Bonnie Ky, MD, MSCE, FACC
University of Pennsylvania School of Medicine
Course Vice Chair
Richard Cheng, MD, FACC
University of Washington
Craig Beavers, PharmD, FACC
Baptist Health System
Alicia Morgans, MD, MPH
Dana-Farber Cancer Institute
Kerry Skurka, RN
Kathleen Zhang, MD, FACC
University of Texas Southwestern Medical Center
Faculty are subject to change without notice.
Disclosure/Conflict of Interest Statement
As a provider jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), the American College of Cardiology Foundation (ACCF) must ensure balance, independence, objectivity and scientific rigor in all of their directly provided or jointly provided/co-provided educational activities. Planners, presenters, and other contributors, in a position to control the content are required to disclose to the audience all relevant financial relationships he/she and/or his/her spouse or domestic partner may have, occurring within the past 24 months, with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the contributor should disclose that the product is not labeled for the use under discussion or that the product is still investigational.
ACCF is committed to providing its learners with high-quality activities and materials that promote improvements and quality in health care and not a specific proprietary business or commercial interest. The intent of this disclosure is not to prevent participation in educational activities by persons with a financial or other relationship, but rather to provide learners with information on which they can make their own determination whether financial interests or relationships may influence the education activity.
ACCF assesses conflicts of interest (COI) with its faculty, planners, managers, staff and other individuals who are in a position to control the content of certified activities. All relevant potential conflicts of interest that are identified are thoroughly vetted by course directors, ACCF education staff, and members of the Accreditation Compliance Workgroup (ACWG) through a process that includes appropriate peer review for fair balance, scientific objectivity and validity, and patient care and safety recommendations.
ACCF has taken the necessary steps to ensure that all relevant financial relationships have been mitigated.
Please note ACCF staff and the ACWG members involved with this activity have nothing to disclose.
2023 Pre-Conference Educational Session
We will kick off Friday evening with an optional, pre-conference session. The 3-hour intensive session will focus on Pharmacology Fundamentals and Imaging Fundamentals.
Friday, April 14, 2023
2:00 p.m. – 6:00 p.m. at Heart House
*Streaming access of this session is Complimentary for virtual attendees of the Advancing the Cardiovascular Care of the Oncology Patient course.
|Registration Fees – VIRTUAL|
|Rate Type||Example Designations||Early Bird
1/19 until 3/15
3/16 through Onsite
|ACC Member Physician||MD, DO||$425||$475||$525|
|Non-Member Physician||MD, DO||$575||$625||$675|
|Reduced (FIT, CVT, Emeritus)||PA, RN, NP, CNS, PharmD, FIT, Resident, Student, and Emeritus||$225||$275||$325|
*Virtual attendees enjoy complimentary access to the Pre-conference Educational Session.
Cancellation, substitution, or transfer to another course is allowed if written notification is received four weeks before a scheduled course. A full refund minus a $250 processing fee will be given for written notifications received fewer than four weeks before the first day of the course. No refund will be given for no-shows.
ACC reserves the right to cancel the course in the unlikely event of insufficient enrollment or other unforeseen circumstances. If a course is canceled or postponed, ACC will refund registration tuition but cannot be held responsible for other costs or expenses, including cancellation/change penalties assessed by airlines, travel agencies or hotels.
Thank you for your interest in submitting an abstract or case for 2023 Advancing the Cardiovascular Care of the Oncology Patient.
Submission Site: Click here to access the abstract and case submission site.
SUBMISSION DEADLINE: All abstracts and cases must be SUBMITTED by 11:59 PM ET on Monday, February 6, 2023 to be considered.
Notification: You will be sent a notification with the status of your submission via email by February 27, 2023. If accepted, you will be directed to register for the course, and you must upload a self-recorded video presentation and/or pdf copy of your poster by March 24, 2023.
Select abstracts and cases will be invited to present in person at Heart House during the course. Those authors will receive special instructions to register when they receive their abstract notification.
All abstracts and cases will be presented as video presentations and/or PDF posters on the course webpage. Changes cannot be made once the abstract or case is submitted.
Please ensure you have thoroughly read the abstract policies and procedures, submission instructions, and the information listed below before submitting your abstract or case.
- Clinical Case Challenge (patient case presentation)
- Original Research Abstracts
- Basic Science in Cardio-Oncology (fundamental or bench research)
- Translational Science in Cardio-Oncology (translating basic science to potential treatment)
- Clinical Science in Cardio-Oncology (collection of evidence to establish treatment)
- Implementation Science (application of research into practice/policy)
- Professional Development Abstracts
- Training and Education in Cardio-Oncology (training curriculum or best practices)
- ACC Cardio-Oncology Section Activities (member activities and outreach)
- Feature Your Cardio-Oncology Clinical Program (establishment and expansion of program)
Contact firstname.lastname@example.org with questions.
Clinical Topics: Cardio-Oncology